Colloidal silver

1. What it was

Version followed: oral, nasal and topical consumer colloidal-silver and silver-salt products as described by the US FDA's 1999 final rule (64 FR 44653), NCCIH, FDA/FTC COVID-19 warning letters (2020) and the Missouri Attorney General's 2021 settlement; the late-1990s "preparedness" variant as reported by the Southern Poverty Law Center and CBS News. This is a historical harm account, not a method a psychotherapist uses. Colloidal silver is not a treatment for cancer, COVID-19 or any other disease.

What it is. A liquid containing tiny silver particles, sold mainly online as a "dietary supplement", sometimes labelled as a homeopathic remedy, and also as nasal sprays and topical products [source: NCCIH]. Related products covered by the same FDA rule include silver proteins ("mild" and "strong" silver protein), "silver ion" and various silver salts [source: FDA 1999 final rule].

Origins and history. Silver has been used medicinally since at least the eighth century [source: Griffith et al. 2015]. Before antibiotics it was used for infections and wounds [source: NCCIH]. Doctors largely stopped prescribing silver-based products in the 1920s; argyria (permanent blue-grey skin) had been documented since the early 20th century [source: SPLC 2002]. Comments to the FDA cited a 1930s compilation of 114 argyria cases and physician reviews of cases from the 1940s–50s, with a warning that argyria could re-emerge [source: FDA 1999 final rule].

Who sold and used it, where and when.

1990s revival (US): sold through retail outlets and mail order in products "often of unknown formulation"; marketers claimed effects against hundreds of conditions (one comment to FDA listed more than 650 diseases) [source: FDA 1999 final rule].
Y2K and "Patriot" preparedness expos (late 1990s): antigovernment and survivalist audiences, fearing antibiotic shortages, were sold silver products and home-production kits alongside water purifiers, freeze-dried food and gas masks; advertising claimed it was effective against "more than 650 diseases" with "NO side effects" and framed it as a cure the government was hiding [source: SPLC 2002].
Public-figure case: Stan Jones, Libertarian US Senate candidate in Montana, began making and taking it in 1999 over Y2K fears; his skin turned blue-grey, became publicly visible during a 2002 campaign, and remained so after he stopped [source: CBS News 2002; SPLC 2002].
Online era: a 2015 study of Amazon listings found 149 ingestible colloidal-silver liquids, with the most visible products averaging 4.38/5 stars from consumer reviews and marketed for "general health" or detoxification [source: Griffith et al. 2015].
COVID-19 (2020): on 9 March 2020 the FDA and FTC jointly warned seven sellers of teas, essential oils and colloidal silver, including Vital Silver and The Jim Bakker Show, over unsupported coronavirus claims [source: FTC 2020]. Health Canada also asked companies to remove COVID-19 claims for products including colloidal silver [source: SooToday/Canadian Press].

Stated rationale (as promoters stated it, not fact). Silver "kills" bacteria, yeasts and viruses throughout the body; it "boosts" the immune system and helps "fight the pathogens we are exposed to" daily; "ionic silver kills coronaviruses" [source: FDA/FTC warning letter to Colloidal Vitality LLC/Vital Silver, 2020]. Earlier claims cited in the FDA rulemaking included prostate symptoms, acne and skin infections, sinus trouble, cough, stomach pain, anal irritation and sexual performance [source: FDA 1999 final rule]. DermNet lists promotion for arthritis, diabetes, cancer, herpes infections and AIDS [source: DermNet]; a US poison centre lists immunity, diabetes, AIDS, cancer and infections [source: Tennessee Poison Center 2025].

How it was sold. Testimonials (including an animal said to have been saved by it) [source: SPLC 2002]; star ratings and reviews [source: Griffith et al. 2015]; "natural antibiotic" framing for people fearful of shortages or distrustful of government and medicine [source: SPLC 2002]; urgency marketing during outbreaks, e.g. products "flying off the shelves" amid coronavirus concern [source: FDA/FTC warning letter 2020]; and religious broadcasting in which a product was offered to viewers in return for a contribution [source: KY3/AP 2021].

Regulatory status (one line). In the US, OTC drug products containing colloidal silver or silver salts for internal or external use are not generally recognised as safe and effective and are misbranded (21 CFR 310.548, effective 16 September 1999) [source: FDA 1999 final rule]; NCCIH states the FDA has warned it is not safe or effective for any disease or condition [source: NCCIH].

Evidence status (one line). Silver has no known function in the body and is not an essential nutrient; small studies of silver nasal spray for chronic sinusitis found no meaningful benefit; there is no clinical evidence for COVID-19 [source: NCCIH].

2. What was actually done

There was no clinical course, assessment or consent process: colloidal silver was overwhelmingly self-administered by consumers on the advice of sellers, broadcasters, community members or self-described practitioners. A typical trajectory, assembled from the sources below, ran as follows.

Entry point. A person with a chronic or frightening condition (infection, skin disease, prostate symptoms, cancer, HIV, diabetes), or a fear of future illness (Y2K, a pandemic), met the product through an expo, a newsletter, a website or social-media page, an online marketplace, or a television programme [source: FDA 1999 final rule; SPLC 2002; Griffith et al. 2015; FDA/FTC warning letter 2020].
Persuasion instead of consent. Claims of broad antimicrobial action and "no side effects" were presented without disclosure of argyria or drug interactions [source: SPLC 2002]. On The Jim Bakker Show, Jim Bakker and a guest introduced as a "naturopathic doctor" discussed the product as a possible coronavirus remedy across 11 episodes in February–March 2020; the guest said it had eliminated other coronavirus strains within 12 hours, and the product was offered to viewers who contributed $80–$125 [source: KY3/AP 2021; FoodNavigator 2020]. Bakker's attorney said Bakker never claimed it cured COVID-19 and stopped offering it after the federal letters [source: KY3/AP 2021].
Obtaining the product. Bought as a "supplement", nasal spray or topical product, often of unknown composition; one comment to the FDA reported that many tested products contained no silver or did not match their labelled particle size [source: FDA 1999 final rule]. Some people made it at home following online instructions or expo demonstrations using electrical "generator" kits [source: DermNet; SPLC 2002; CBS News 2002].
Administration (qualitative only). Usually taken by mouth, typically from a dropper; also used as nasal sprays, on the skin, and occasionally labelled for intravenous use [source: FDA 1999 final rule; Tennessee Poison Center 2025]. Harmful cases describe repeated daily ingestion over months to years [source: Mirsattari et al. 2004; DermNet].
Judging "progress". By symptom relief that the person attributed to silver (Stan Jones, for instance, said it cured his psoriasis), by testimonials and by product reviews; no objective monitoring [source: SPLC 2002; Griffith et al. 2015]. FDA noted that testimonials cannot establish safety or effectiveness [source: FDA 1999 final rule].
Handling non-response or harm. Promoters' framing (a suppressed cure, no side effects) left little room to interpret worsening as harm. One user who developed argyria later attributed it to not having studied how to make it "properly" rather than to silver itself [source: SPLC 2002]. Users who also took antibiotics or thyroid medication were not warned that silver can reduce absorption of these drugs [source: NCCIH] [synthesis on the absence of warnings, inferred from the marketing described].

Named variants. "Colloidal silver"; "ionic silver"; "structured silver" (e.g. "Structured Silver Advanced Formula") [source: FDA/FTC warning letter 2020]; "Silver Solution" (The Jim Bakker Show) [source: KY3/AP 2021]; silver proteins and silver salts [source: FDA 1999 final rule]; homeopathic silver products [source: NCCIH]; home-made colloidal silver [source: DermNet].

3. How it caused harm

Argyria (skin and mucosal discolouration).

Mechanism: absorbed silver circulates bound to albumin and deposits as silver salts in skin, liver, spleen and adrenal glands; discolouration is darkest where sunlight hits, from silver deposits plus increased melanin; severity depends on form, amount, duration and route [source: DermNet].
Course: often begins as grey-brown staining of the gums and spreads over months to years to the face (forehead, nose), neck, arms and hands; nails, conjunctivae and mucous membranes may darken; sometimes the whole skin becomes slate blue-grey [source: DermNet].
Permanence: NCCIH calls it "usually permanent" [source: NCCIH]; DermNet describes it as permanent and almost untreatable, with depigmenting agents and chelation ineffective and a specific laser reported as helpful [source: DermNet]. It is rare and may be misdiagnosed; diagnosis is by skin biopsy [source: DermNet].
Case example (public figure): Stan Jones' blue-grey skin persisted after stopping [source: CBS News 2002]. A comment to the FDA described a person disfigured by argyria for 40 years [source: FDA 1999 final rule].

Neurological, kidney and liver harm. NCCIH reports some evidence of kidney, liver and nervous-system problems [source: NCCIH]; long-term ingestion has been associated with renal, hepatic and neurological harms [source: Griffith et al. 2015]. In a published case, a 71-year-old man who took colloidal silver by mouth daily for four months developed myoclonic status epilepticus and coma with high silver levels in blood and cerebrospinal fluid; plasmapheresis did not help, and he died in a persistent vegetative state 5.5 months later. The authors concluded that silver products can cause irreversible neurological toxicity [source: Mirsattari et al. 2004].

Drug interactions. Colloidal silver can reduce absorption of some medicines, including certain antibiotics and thyroxine (used for thyroid deficiency) [source: NCCIH]. Clinically this risks treatment failure of an infection or under-treatment of hypothyroidism; any concern goes to the prescriber or pharmacist [synthesis].

Delayed or forgone care. Because the product was sold as treating serious infections, cancer, HIV and COVID-19, the main indirect harm is delay in seeing a clinician; NCCIH advises not to delay care because of colloidal silver or any unproven product [source: NCCIH]. Health Canada advised people using such products against COVID-19 to stop and speak with a health professional [source: SooToday/Canadian Press]. Specific documented deaths from delayed care attributable to colloidal silver are [uncertain: not verified].

Financial and exploitative harm. Purchases tied to fear (Y2K, pandemics) and to religious giving (contributions of $80–$125 for a product on a church broadcast) [source: SPLC 2002; KY3/AP 2021]. The Missouri settlement required $156,000 in restitution to people who paid or contributed for Silver Solution, barred disease claims for it, and contained no admission of wrongdoing; Arkansas filed a similar suit in 2020 [source: KY3/AP 2021].

Psychological sequelae. Visible, usually permanent discolouration plausibly brings shame, social withdrawal, stigma, body-image distress, regret and self-blame; the cited sources do not quantify this [uncertain: not verified] [synthesis]. Users drawn in through distrust of government or medicine may find accepting harm threatens their identity and community ties, as in a user who continued to defend the remedy after argyria [source: SPLC 2002] [synthesis on interpretation].

Who was most at risk. Long-term daily users and those making it at home (unknown composition) [source: DermNet; FDA 1999 final rule]; people with serious or chronic illness seeking alternatives (cancer, HIV, infections) [source: DermNet; Tennessee Poison Center 2025]; people on antibiotics or thyroid replacement [source: NCCIH]; survivalist or antigovernment communities [source: SPLC 2002]; frightened audiences during outbreaks, including viewers of religious broadcasting [source: FTC 2020; KY3/AP 2021]; older adults [synthesis, from the case literature above].

4. Recognising it today

Product names and forms to listen for. "Colloidal silver", "ionic silver", "structured silver", "silver hydrosol" or "silver water", "mild silver protein", "nano-silver", homeopathic silver; drops, sprays, gels, "immune" blends, and home "generator" kits [source: FDA 1999 final rule; FDA/FTC warning letter 2020; NCCIH; DermNet; SPLC 2002]. "Silver hydrosol", "silver water" and "nano-silver" as trade terms are [uncertain: not verified] in the sources listed here.

Claims and phrases that signal it.

"Natural antibiotic", "kills bacteria, viruses and yeast/candida", "boosts immunity", "fights the pathogens we meet every day" [source: FDA/FTC warning letter 2020].
"Works against 650 diseases", "no side effects", "what they don't want you to know" [source: SPLC 2002; FDA 1999 final rule].
"Kills coronaviruses" or any outbreak-linked claim; "flying off the shelves" urgency [source: FDA/FTC warning letter 2020].
"Eliminates toxins, poisons and fungi" (detox framing) [source: Griffith et al. 2015].
Being stockpiled as an antibiotic substitute in preparedness or anti-government settings [source: SPLC 2002].
Offered in return for a donation by a ministry or broadcaster [source: KY3/AP 2021].

Clinical clues in a client. Blue-grey or slate-grey skin, darkest on the face, neck and hands; grey gums, nails or eye membranes [source: DermNet]. Repeated antibiotic failure or unstable thyroid treatment in someone who takes silver may warrant a prompt to tell the prescriber [source: NCCIH] [synthesis]. Statements such as "I treat my own infections" or "I don't need antibiotics" [synthesis].

Red flags in a colleague's or service's practice [synthesis, informed by the regulatory sources above].

Recommending, selling, stocking or affiliate-linking silver products, or presenting them as treating infection, cancer, HIV, COVID-19 or "immunity".
Advising a client to delay, reduce or stop medical treatment (including antibiotics or thyroid medicine) in favour of silver.
Using testimonials or reviews as evidence; FDA states testimonials cannot establish safety or effectiveness [source: FDA 1999 final rule].
Linking products to donations, membership or spiritual standing.
Dismissing argyria as a matter of "wrong preparation" rather than silver itself [source: SPLC 2002 for this argument].

How legitimate uses differ. Silver's antibacterial properties are used in medical equipment, wound dressings and prescribed topical creams such as silver sulfadiazine; these are regulated medical uses under clinical supervision, not oral consumer use, which has no supported benefit [source: Tennessee Poison Center 2025]. A therapist need not judge any medical silver product; questions go to the treating clinician [synthesis].

Regulatory baseline to cite when a client asks "is it allowed?" US: the 1999 rule (OTC silver drug products not GRAS/E, misbranded); any product promoted to treat or prevent disease is an unapproved new drug [source: FDA 1999 final rule]; disease claims without competent and reliable scientific evidence breach the FTC Act [source: FDA/FTC warning letter 2020]. Canada: false or misleading health-product claims are illegal [source: SooToday/Canadian Press]. UK, EU and Australian positions on colloidal silver are [uncertain: not verified].

5. What to do instead and how to help those harmed

What to use instead. For infections, thyroid disease, cancer, HIV, COVID-19 or any physical illness: assessment and evidence-based treatment by the client's own clinicians; NCCIH's advice is not to delay seeing a provider because of colloidal silver and to tell all providers about complementary approaches [source: NCCIH]. For suspected silver exposure or acute concern in the US: a poison centre (Poison Help, 1-800-222-1222) [source: Tennessee Poison Center 2025]. For argyria: dermatology assessment; DermNet lists stopping all silver, sunscreen, cosmetic camouflage and reports one laser treatment as helpful [source: DermNet]. For the fears that drove use (pandemic, shortages, illness): psychological care for health anxiety and uncertainty, see Domain II [synthesis]. The psychotherapist never recommends, sells or supplies silver or any alternative product, and never advises starting, stopping or changing any medicine or remedy; those questions go to the prescriber or pharmacist [synthesis].

The psychotherapist's own work follows. All steps and wording below are [synthesis] unless a source is cited.

5.1 Asking about use routinely and without judgement

Purpose / when: at intake and at reviews, and whenever a client mentions infection, immunity, "detox", preparedness, a serious diagnosis or unexplained grey skin. Clinicians are urged to ask about supplements and alternative remedies in every history [source: Griffith et al. 2015; NCCIH].
Steps: (1) Ask a general, normalising question about remedies and supplements; (2) if silver is named, ask what form, for how long, why, and where it comes from (bought, gifted, home-made), without asking about amounts beyond what a doctor would need; (3) ask whether their doctors know; (4) record the product, reason and whether medical care is involved; (5) note any skin, neurological or medication-related concerns for referral.
Example language (illustrative): "Lots of people use remedies or supplements alongside, or instead of, what doctors offer. Are you using anything like that at the moment?" / "What made silver feel like the right choice for you?"
Watch for: shame or defensiveness (slow down, return to curiosity); disclosure that it replaces antibiotics, thyroid medicine or cancer treatment; children being given it; it is working when the client speaks openly and agrees the doctor should know.

5.2 Exploring meaning, hopes and the explanatory model

Purpose / when: after disclosure, to understand what silver does for the client: control, hope, self-reliance, distrust of medicine or government, belonging to a preparedness, wellness or faith community, or loyalty to a trusted broadcaster or leader [source: SPLC 2002 and KY3/AP 2021 for these contexts; synthesis for the clinical use].
Steps: (1) Elicit their account of illness and of how silver works, in their words; (2) ask what they hope it will do and what they fear if they stop; (3) ask who recommended it and what that relationship means; (4) reflect values (protecting family, independence, faith) separately from the product; (5) note where values could be honoured by safer means.
Example language (illustrative): "It sounds like being able to look after yourself, without depending on a system you don't trust, matters a lot." / "If it worked exactly as you hope, what would be different?"
Watch for: beliefs held with group or identity stakes (challenge raises loyalty); signs of high-control group dynamics; it is working when the client distinguishes their values from the product.

5.3 Autonomy-respecting decision support

Purpose / when: when a client is deciding whether to start, continue or rely on silver, especially for a serious illness. Adults decide; the therapist's task is informed, uncoerced choice, not persuasion [synthesis].
Steps: (1) Ask permission to share what health authorities say; (2) offer balanced, sourced information: no known benefit in the body, risk of usually permanent argyria, possible kidney, liver and nerve effects, reduced absorption of some antibiotics and thyroxine [source: NCCIH]; (3) ask what they make of it; (4) separate two questions: "use silver?" and "also see my doctor?"; (5) encourage the medical conversation, offering to help them prepare questions; (6) document the discussion and their decision. No published decision aid specific to colloidal silver was found [uncertain: not verified].
Example language (illustrative): "Would it be OK if I shared what the US health agencies say about silver? You can take it or leave it." / "Whatever you decide about silver, could we make sure your doctor is still part of the picture?"
Watch for: your own urge to argue (it increases resistance); misunderstanding of risk (check back); it is working when the client can state the risks in their own words and keeps or books medical contact.

5.4 Coordination with physicians, pharmacists, oncology and palliative teams

Purpose / when: whenever silver is used alongside prescribed medicines, during cancer or other serious treatment, or when there are skin, neurological, kidney or liver concerns.
Steps: (1) Seek written consent to contact the GP or physician, pharmacist, oncologist or palliative team; (2) share only what the client agrees: product, reason, duration, and the therapist's psychological formulation; (3) ask the medical team to address interactions and physical risk (the therapist does not); (4) agree who follows up; (5) where a client with cancer chooses silver instead of treatment, support continued contact with oncology and early palliative-care involvement if they wish; (6) document.
Example language (illustrative): "Your doctor needs to know about the silver to keep your other treatment working well. Would you like to tell them yourself, or shall I write with your permission?"
Watch for: refusal of consent (respect it unless a safeguarding threshold is met; keep the door open); split messages between team members; it is working when the medical team is informed and the client stays engaged with both.

5.5 Supporting a client living with argyria

Purpose / when: a client with blue-grey discolouration, often permanent [source: NCCIH; DermNet].
Steps: (1) Ensure dermatology involvement and that silver use has stopped, as dermatology advises [source: DermNet]; (2) assess shame, social avoidance, low mood, suicidality and body-image distress with standard measures and risk assessment; (3) work with appearance-related distress using established CBT or compassion-focused approaches (see Domain II); (4) address self-blame and regret (5.6); (5) plan for others' reactions, including scripts for strangers' questions; (6) discuss cosmetic camouflage as an option the client can explore with dermatology [source: DermNet for camouflage].
Example language (illustrative): "You chose silver to protect your health with what you knew then. The colour is a consequence, not a verdict on you." / "What do you want to say when someone asks about your skin?"
Watch for: withdrawal, depression or suicidal thoughts; the client still using silver; it is working when avoidance falls and the client re-enters valued activities.

5.6 Grief, regret and family conflict

Purpose / when: after a person was harmed or died, or when family members disagree about a relative's use, especially in cancer or other serious illness.
Steps: (1) Hear each person's account; (2) name grief, guilt, anger and regret as understandable; (3) separate responsibility from blame (the role of misleading marketing is documented [source: FTC 2020; KY3/AP 2021]); (4) in families, help members voice fear and love behind the conflict and agree how to talk to the ill person; (5) for bereavement, offer grief-focused work and screen for prolonged grief and depression; (6) where a family member chose silver over treatment, support the family to stay connected while respecting the adult's decision.
Example language (illustrative): "You're angry because you love him and you're frightened. He may be choosing silver for reasons that are about hope." / "Many people were persuaded by confident, repeated claims. That's not foolishness."
Watch for: blame fixing on the ill person; estrangement; complicated grief; it is working when family members can talk with, not at, each other.

5.7 Financial harm and exploitation

Purpose / when: when money spent on silver products, kits or donation-linked offers causes hardship, or when a client is pressured by a seller, network-marketing upline, ministry or community.
Steps: (1) Ask how much has been spent and on what, and whether there is pressure to buy more or recruit others; (2) explore feelings (embarrassment, betrayal, loyalty); (3) tell the client that regulators have taken action against sellers and that restitution has been ordered in at least one case (Missouri, $156,000) [source: KY3/AP 2021]; (4) signpost consumer-protection reporting (5.10) and money advice; (5) where the seller is a trusted religious or community figure, help the client weigh faith and belonging separately from the purchase.
Example language (illustrative): "Being asked to give money for a health product during a frightening time is something regulators have acted on. You're allowed to question it."
Watch for: ongoing payments, debt, isolation from non-believing family, recruitment pressure; it is working when spending stops or the client makes a deliberate, informed choice.

5.8 Fear-driven use, health anxiety and preparedness worries

Purpose / when: when silver is used to manage fear of infection, pandemics or loss of medical supply, as in the Y2K and COVID-19 waves [source: SPLC 2002; FTC 2020].
Steps: (1) Assess for health anxiety, generalised anxiety or illness-focused OCD; (2) formulate stockpiling and self-dosing as safety behaviours that relieve fear briefly and maintain it; (3) treat with established CBT for health anxiety and intolerance of uncertainty (see Domain II), without targeting the client's politics or faith; (4) help build a realistic, medically endorsed preparedness plan with the GP (e.g. how to access care) rather than self-treatment.
Example language (illustrative): "When the news gets scary, what does having silver in the cupboard do for the fear?" / "Let's find ways to feel prepared that don't carry a risk to your skin or your medicines."
Watch for: substitution of one safety product for another; it is working when reassurance-seeking and self-treatment fall.

5.9 Safeguarding children and adults at risk

Purpose / when: a child, pregnant person or adult lacking capacity is given silver, or is kept from medical care, antibiotics or prescribed medicines in favour of it.
Steps: (1) Clarify facts: who gives it, why, whether medical care is being withheld; (2) consider assent and consent: a child cannot consent to an unproven product and parental consent does not extend to depriving a child of needed care [synthesis]; (3) consult your safeguarding lead; (4) if a child's health is at risk through withheld care or a harmful product, refer under local child-protection procedures; (5) for adults at risk, follow adult-safeguarding procedures; (6) document reasoning and actions; (7) for acute concerns, direct to emergency care or poison control. Child-specific clinical reports involving colloidal silver are [uncertain: not verified].
Example language (illustrative): "I can hear how much you want to protect her. Because she can't choose for herself, I need to make sure her doctor is involved."
Watch for: escalating secrecy, missed medical appointments, visible discolouration in a child; never name children in records shared outside the clinical file beyond what procedures require.

5.10 Reporting

Purpose / when: a product is sold with disease claims, a client is harmed, or a professional promotes it.
Steps / routes:
- US adverse events from supplements: the HHS Safety Reporting Portal (safetyreporting.hhs.gov) [source: NCCIH].
- US false health claims and scams: ReportFraud.ftc.gov [source: FTC 2020]; state attorneys general have sued sellers (Missouri, Arkansas) and issued cease-and-desist orders (New York) [source: KY3/AP 2021; FoodNavigator 2020].
- Canada: Health Canada treats false or misleading health-product claims as illegal and works with the Competition Bureau [source: SooToday/Canadian Press]; the specific reporting form is [uncertain: not verified].
- UK (MHRA Yellow Card, Advertising Standards Authority), Australia (TGA) and other jurisdictions: [uncertain: not verified]; use the national medicines or product regulator and the advertising regulator.
- Professionals: the practitioner's licensing or registration board if a regulated professional sells or recommends silver as treatment [synthesis].
- Reporting with identifiable client information requires the client's consent unless a legal or safeguarding duty applies [synthesis].
Example language (illustrative): "You can report the seller yourself, anonymously if you prefer, and I can show you where."
Watch for: the client's fear of their community's reaction; it is working when the client feels choice and support, not pressure.

5.11 Therapist boundaries and conflicts of interest

Purpose / when: throughout; especially if the therapist is personally interested in natural remedies or is asked for an opinion.
Steps: (1) Do not sell, recommend, supply or endorse silver or any product; (2) keep within scope: physical risk and medicines belong to clinicians; (3) declare and avoid any financial link to remedy sellers; (4) seek supervision where your own views (for or against) are strong. The APA Ethics Code (https://www.apa.org/ethics/code) is relevant to competence, conflicts of interest and avoiding harm; specific clause numbers are [uncertain: not verified] [synthesis].
Example language (illustrative): "It's not my role to recommend or rule out products, but I can help you think it through and make sure the right person checks it."
Watch for: drifting into giving medical advice or arguing; it is working when the client feels respected and medical questions reach a clinician.

5.12 Common difficulties and responses [synthesis]

"My doctor will just dismiss me." Help the client prepare a short script and questions; offer a joint letter with consent; validate past experiences of not being heard.
Client keeps using despite argyria. Respect autonomy; keep medical contact; explore what stopping would mean (loss of control, admitting harm, community loyalty).
Conspiratorial frame ("they hide the cure"). Avoid debate about the frame; explore the experiences behind distrust; focus on shared goals such as health and independence.
Overwhelm after learning about harm. Slow pacing, grounding, and separating facts from self-blame; screen for risk.
Rupture when the therapist raises risk. Acknowledge the impact, restate respect for the client's choice, and repair before returning to information.
Family insisting the therapist "make them stop". Clarify confidentiality and role; offer family sessions with consent; safeguarding only where thresholds are met.

Ethical, reporting and legal duties (summary). Stay within competence; never advise on medicines; obtain consent before contacting other professionals; follow child and adult safeguarding law and local procedures; report products and false claims through the routes in 5.10; document decisions [synthesis; source for routes as cited in 5.10].

Sources

← Previous · XII-141Chlorine dioxide (MMS)Next · XII-143 →DMSO